Clinical trials: Advanced Solid Tumor or Lymphoma
Advanced Solid Tumor, Lymphoma
Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas
This will be a Phase 1, open-label study of DS-8273a to assess its safety and tolerability, identify the Maximum Tolerated Dose and/or Maximum Administered Dose, and assess its properties in subjects with advanced solid tumors or…
- Trial name
- NCT02076451
- Testing
- DS-8273a
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Solid Tumors and Lymphomas
Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
The purpose of this study was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) in combination with PDR001.
- Trial name
- NCT03172936
- Testing
- MIW815, PDR001
- Where
- 12 sites in United States, Australia and 6 more
- Volunteers
- 106 people
- Sponsor
- Novartis Pharmaceuticals
Advanced/Metastatic Solid Tumors, Relapse/Refractory Lymphoma
First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
For solid tumors and lymphoma, respectively: This study is to evaluate the safety and tolerability of EMB-07 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D).
- Trial name
- NCT05607498
- Testing
- EMB07
- Where
- 10 sites in Australia, China
- Volunteers
- 150 people
- Sponsor
- EpimAb Biotherapeutics (Suzhou)Co., Ltd.
Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Peripheral/Systemic Lymphoma
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
This phase I trial is studying the side effects and best dose of giving tanespimycin together with bortezomib in treating patients with advanced solid tumors or lymphomas.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Peripheral/Systemic Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00096005
- Testing
- tanespimycin, bortezomib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Colorectal Cancer
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.
- Conditions
- Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma
- Trial name
- NCT03422679
- Testing
- CB-103
- Where
- 17 sites in United States, France and 4 more
- Volunteers
- 79 people
- Sponsor
- Cellestia Biotech AG
Advanced Cancer, Solid Tumor, Adult
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies
This is an open-label, non-randomized, Phase 1 study to determine the safety, tolerability, and preliminary efficacy of MCLA-145 in adult patients with advanced metastatic solid tumors or B-cell lymphomas.
- Conditions
- Advanced Cancer, Solid Tumor, Adult, B-cell Lymphoma, Adult
- Trial name
- NCT03922204
- Testing
- MCLA-145, Pembrolizumab (Keytruda)
- Where
- 8 sites in United States, Belgium and 2 more
- Volunteers
- 72 people
- Sponsor
- Merus B.V.
Locally Advanced /Metastatic Solid Tumors, Relapsed or Refractory Lymphomas
A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas
A multicenter, open-label, dose-escalation and dose-expansion phase 1/2 study, to evaluate TY101 safety, tolerability, pharmacokinetic characteristics, effectiveness and immunogenicity in patients with Locally Advanced…
- Trial name
- NCT04458389
- Testing
- TY101
- Where
- 3 sites in China
- Volunteers
- 268 people
- Sponsor
- Tayu Huaxia Biotech Medical Group Co., Ltd.
Solid Tumors, B Cell Lymphoma
Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas
Determine alone or in combination with chemotherapy or autologous cytokine induced killer cells are effective and safe in the treatment of patients with relapsed and/or refractory solid tumors or B Cell lymphomas.
- Trial name
- CIK (NCT01799083)
- Testing
- Decitabine, cytokine-induced killer cell
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Han weidong
Neoplasms Malignant
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104
This was a first-in-human, Phase 1 study designed to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK117 as monotherapy or in combination with AK104 in subjects…
- Trial name
- NCT04349969
- Testing
- AK117, AK117+AK104
- Where
- 4 sites in Australia
- Volunteers
- 38 people
- Sponsor
- Akesobio Australia Pty Ltd
Solid Tumor, Non Hodgkin Lymphoma
Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma
This is a Multicenter, Open-Label, Phase Ib/II Study of ADG106 in Combination with PD-1 Antibody in Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.
- Trial name
- NCT04775680
- Testing
- ADG106 injection, PD-1 antibody injection
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Adagene (Suzhou) Limited
FL Lymphoma, Epithelioid Sarcoma
Evaluate the Safety and Clinical Activity of HH2853
This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II.
- Conditions
- FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
- Trial name
- NCT04390737
- Testing
- HH2853 Tablets
- Where
- 25 sites in United States, China
- Volunteers
- 254 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Solid Tumor, Glioma
Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
The purpose of this study is to evaluate the safety, pharmacokinetics, and clinical activity of enasidenib in adults with advanced solid tumors, including glioma, or with angioimmunoblastic T-cell lymphoma (AITL), with an…
- Conditions
- Solid Tumor, Glioma, Angioimmunoblastic T-cell Lymphoma, Intrahepatic Cholangiocarcinoma
- Trial name
- NCT02273739
- Testing
- Enasidenib
- Where
- 12 sites in United States, France
- Volunteers
- 21 people
- Sponsor
- Celgene
Tumors, Lymphoma
A Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors and Lymphoma
This study will research the side effects of pegaspargase (pronounced "peg-as-par-gase"); its brand name is ONCASPAR® when it is used with another FDA-approved cancer treatment (chemotherapy) drug called gemcitabine HCl…
- Trial name
- NCT00363610
- Testing
- Oncaspar & Gemzar; advanced and/or solid tumors and lymphoma
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Enzon Pharmaceuticals, Inc.
Solid Tumor, Lymphoma
Clinical Trial of HG146 Administered to Subjects With Advanced Solid Tumors or Lymphoma
This is a Phase I, open-label, repeat-dose, non-randomized, multicenter study to evaluate the safety, tolerability, and preliminary clinical activity and establish a recommended dose of HG146 administered orally (PO) alone (Part…
- Trial name
- NCT04977167
- Testing
- HG146, PD-(L)1 antibody
- Where
- China
- Volunteers
- 24 people
- Sponsor
- HitGen Inc.
Neoplasm, Lymphomas
Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas
Studies of PEG-paclitaxel have been terminated
- Conditions
- Neoplasm, Lymphomas, Neoplasm Metastasis
- Trial name
- NCT00023166
- Testing
- PEG-paclitaxel
- Sponsor
- Enzon Pharmaceuticals, Inc.
Non-Hodgkin's Lymphoma, Solid Tumor
Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma
This is an open-label, multicenter, Phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetic (PK) of GDC-0349 administered once daily (QD), orally (PO).
- Trial name
- NCT01356173
- Testing
- GDC-0349
- Where
- 2 sites in United States, Canada
- Volunteers
- 10 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumor, Lymphoma
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
DS-3078a will be evaluated as a single agent in subjects with advanced solid tumor malignancies or lymphomas refractory to standard treatment or for which no standard treatment is available.
- Trial name
- NCT01588678
- Testing
- DS-3078a
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Solid Tumors, Lymphoma
Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma
The primary objective of this study in adults with advanced or recurrent solid tumors or lymphoma is to evaluate the safety and tolerability of AR-12 by describing dose-limiting toxicities (DLTs), and thereby establishing the…
- Trial name
- NCT00978523
- Testing
- AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide)
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 35 people
- Sponsor
- Arno Therapeutics
Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of dasatinib in treating patients with solid tumors or lymphomas that are metastatic or cannot be removed by surgery.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia, Adult Hepatocellular Carcinoma, Adult Nasal Type Extranodal NK/T-Cell Lymphoma
- Trial name
- NCT00608361
- Testing
- Dasatinib, Pharmacological Study
- Where
- 23 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
The purpose of the study is to assess the safety, tolerability, pharmacokinetics and immunoregulatory activity of urelumab (BMS-663513) in cancer subjects with advanced and/or metastatic tumors and relapsed/refractory B-Cell…
- Trial name
- NCT01471210
- Testing
- Urelumab (BMS-663513)
- Where
- 24 sites in United States, France and 2 more
- Volunteers
- 124 people
- Sponsor
- Bristol-Myers Squibb